Research.Patient.info
Juvenile Dermatomyositis research hub
2 indexed studies · 2 currently recruiting
- recruitingTherapeutic exploratory (Phase II)
MYOCIT - Baricitinib in the treatment of new-onset juvenile dermatomyositis: a phase II trial
This study, called MYOCIT, is looking at a medicine called baricitinib for young people with a new diagnosis of juvenile dermatomyositis. It's a Phase II trial, meaning doctors want to see how well it works and if it's safe. They'll measure improvements in symptoms like muscle strength and skin rashes.
France - recruitingPHASE2, PHASE3
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
This study looks at a new treatment called CABA-201 for conditions that cause muscle weakness and inflammation, like dermatomyositis. It aims to see how safe and effective this treatment is for adults and children whose condition hasn't improved with usual care.
United States · Germany · Italy